Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 19;8:252. doi: 10.1038/s41392-023-01495-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — Comparison of humoral immune response after BA.5 infection with different number of vaccinations. a 64 adult (aged from 18–65) participants who have received injections of inactivated vaccines with infection were then divided into two cohorts: two doses of inactivated vaccine group (n = 25), and 3 doses of inactivated group (n = 39). The endpoint titers of wildtype and BA.5 spike-specific binding antibodies in sera were determined. b Neutralizing antibody titers against prototype, Delta, BA.1, BA.2, BA.2.75, BA.3 pseudoviruses in sera from adult participants with different number of vaccinations. c Neutralizing antibody titers to BA.4/5, BF.7, BQ.1, BQ.1.1, XBB and XBB.1.5 pseudoviruses in serum samples. (n = 25 in 2 dose of IV group, and n = 39 in 3 dose of IV group in a–c). d Endpoint titers of wildtype spike-specific binding antibodies IgG and IgG in nasal samples. e Neutralizing antibody titers to BA.1, BA.4/5, BQ.1 and XBB pseudoviruses in nasal swab samples. (n = 12 in 2 dose of IV group, and n = 14 in 3 dose of IV group in d, e). Data are presented as geometric mean values ± SD in (a–e). P values were determined by unpaired Student’s t tests. ns not significant